Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 4

04:18 EST 22nd February 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 76–100 of 6,200+

Probably Relevant

Soleno Therapeutics Announces Issuance Of New U.S. Patent For DCCR Covering Treatment Of Hyperphagia In Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (9,782,416) from the U.S. Patent and Trademark Office related...


CureVac and Arcturus Therapeutics announce broad strategic collaboration

CureVac AG and Arcturus Therapeutics Ltd. announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics. Under the agreement, the companies will collaborate to develop up to four molecular therapy products for ...

ACORDA THERAPEUTICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acorda Therapeutics, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acorda Therapeutics, Inc. ("Acorda" or the "Company") (NASDAQ: ACO...


Active-Investors: Research Reports on, Cronos Group, Antibe Therapeutics, Emerald Health Therapeutics, and BriaCell Therapeutics

LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Cronos Group, Antibe Th...

Financial Analysis: Aptevo Therapeutics

Aptevo Therapeutics and Array BioPharma are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends. This is a summary of current recommendations and price targets for Aptevo Therapeutics and Array BioPharma, as provided by...

Arcturus, Ultragenyx ally in rare disease pact worth up to $1.6bn

RNA-focused start-up Arcturus Therapeutics Inc. (ATI) and fellow rare disease therapeutics developer Ultragenyx Pharmaceutica...

Celgene signs $9bn acquisition deal with Juno Therapeutics

Celgene has entered a definitive merger agreement to acquire US-based biopharmaceutical firm Juno Therapeutics for $87 per share, totalling approximately...Read More... The post Celgene signs $9bn acquisition deal with Juno Therapeutics appeared first on Pharmaceutical Technology.

FDA approves Spark Therapeutics’ Luxturna for retinal dystrophy

Spark Therapeutics has gained US Food and Drug Administration (FDA) approval for its one-time gene therapy product, Luxturna (voretigene neparvovec-rzyl),...Read More... The post FDA approves Spark Therapeutics’ Luxturna for retinal dystrophy appeared first on Pharmaceutical Technology.

Edison Issues Update on e-Therapeutics (ETX)

LONDON, UK / ACCESSWIRE / January 5. 2018 / e-Therapeutics' (LSE: ETX) Network-Driven Drug Discovery (NDD) platform has begun to deliver encouraging data that should support out-licensing of its i...

Amylon Therapeutics wins Startup Slam Competition at BIO-Europe® Berlin

Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the oppo...

What You Need to Know About Jecure Therapeutics

Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis.

ASH Preview 2 – Developmental Therapeutics

One of my favourite areas to follow in oncology research is Developmental Therapeutics, whether they be targeted, genomic, epigenetic or…

BRIEF—Semma Therapeutics raises $114 million Series B financing

Semma Therapeutics, which is focused on the development of novel regenerative medicines, announced today…

BRIEF — UCB and investor syndicate led by Novo Seeds launch Syndesi Therapeutics

The creation of Syndesi Therapeutics was announced on Thursday as the result of a partnership between…

CorFlow Therapeutics gets $2.62M boost

A round of seed financing brought in approximately $2.63 million for CorFlow Therapeutics, a Switzerland-based company that i -More- 

What You Need to Know About Corbin Therapeutics

Corbin Therapeutics, headquartered in Montreal, Quebec, was spun out of venture capital company AmorChem.

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

The Dimension Therapeutics CEO succeeds Dr Stephen Parker, who becomes a non-executive director

Juno Therapeutics signs a trio of licensing deals

USA-based Juno Therapeutics rose 4% in pre-market trading, after it announced three license agreements…

Funding round brings in $25M for SPR Therapeutics

A round of Series C financing brought in $25 million for Cleveland-based medical device startup SPR Therapeutics.  -More- 

Finch, Crestovo combine to develop microbiome pipeline

Finch Therapeutics and Crestovo agreed to merge, forming Finch Therapeutics Group, which will focus on manufacturing candidat -More- 

Spark Therapeutics Shares Halted as FDA Committee Reviews Luxturna for Eye Disease

Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging...

SPR Therapeutics secures funding to commercialise Sprint PNS system

SPR Therapeutics, a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain, has announced the completion of $25m in series C financing.

What You Need to Know About Immune-Onc Therapeutics

Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.

Big bets being placed on Tmunity Therapeutics

If the $100 million total raised by Tmunity Therapeutics in a Series A financing is not evidence enough…


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks